Teva Pharmaceutical (TEVA) stock is trading higher on Wednesday, following the company's beat in its first quarter earnings report. Contributing further to the rally, Teva unveiled encouraging results from a clinical study evaluating its Schizophrenia treatment, Olanzapine, driving shares higher.

Yahoo Finance's health reporter Anjalee Khemlani breaks down the details.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Angel Smith